Julia K. Tietze

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann, Andrea Forschner, Carmen Loquai et al. · European Journal of Cancer · 2016 · 638 citations

Urology, Hepatology, Anti-pd-1 Therapy +9

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Lisa Zimmer, Simone M. Goldinger, Lars Hofmann et al. · European Journal of Cancer · 2016 · 552 citations

Translational Medicine, Heart Failure, Cardiovascular Disease +4

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler et al. · European Journal of Cancer · 2017 · 196 citations

Prognostic Factors, Programmed Cell Death-1, Medicine +9

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

Lisa Ann Gerdes, Kathrin Held, Eduardo Beltrán et al. · Annals of Neurology · 2016 · 116 citations · Full text

Clinical Immunology, Lymphocyte Development, Immunology +23

Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma

Markus V. Heppt, Alexander Roesch, Benjamin Weide et al. · European Journal of Cancer · 2017 · 97 citations

Prognostic Factors, Mucosal Melanoma, Surgical Oncology +10